Thermo Fisher Scientific signed an agreement to acquire Sanofi’s steriles manufacturing site in Ridgefield, NJ, and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will expand the use of the site to meet the demand from pharma and biotech customers for U.S. manufacturing capacity.
The Ridgefield site is a sterile fill-finish and packaging facility with a team of more than 200 employees who will join Thermo Fisher following the completion of the transaction.
“Sanofi’s Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines,” said Marc N. Casper, chairman, president, and CEO of Thermo Fisher. “We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site.”
Brendan O’Callaghan, global head of manufacturing & supply, Sanofi, added, “This expansion of our long-term partnership with Thermo Fisher will help ensure a continued supply of high-quality Sanofi products, maintaining our commitment to American manufacturing and supporting our customers and patients in the U.S., while enabling the future development and growth of the site.”
Thermo Fisher operates a global sterile fill-finish manufacturing network, which currently includes U.S. sites in Greenville, NC, and Plainville, MA. These sites are integral to the company’s Accelerator
Drug Development 360° CDMO and CRO solutions, according to Casper.
Upon completion of the transaction, which is expected to be completed in the second half of 2025, Sanofi’s Ridgefield facility will become part of Thermo Fisher’s pharma services business within its Laboratory Products and Biopharma Services segment.
The post Thermo Fisher Agrees to Acquire Sanofi’s Steriles Manufacturing Site appeared first on GEN – Genetic Engineering and Biotechnology News.
